GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (NAS:VCYT) » Definitions » Total Inventories

Veracyte (Veracyte) Total Inventories : $18.3 Mil (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Veracyte Total Inventories?

Veracyte's total inventories for the quarter that ended in Mar. 2024 was $18.3 Mil. Veracyte's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $17.2 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Veracyte's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $2.25.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Veracyte's Days Inventory for the three months ended in Mar. 2024 was 49.97.

Inventory Turnover measures how fast the company turns over its inventory within a year. Veracyte's Inventory Turnover for the quarter that ended in Mar. 2024 was 1.83.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Veracyte's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.18.


Veracyte Total Inventories Historical Data

The historical data trend for Veracyte's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte Total Inventories Chart

Veracyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.81 4.66 11.23 14.29 16.13

Veracyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.31 11.57 15.89 16.13 18.33

Veracyte Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Veracyte  (NAS:VCYT) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Veracyte's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

Net-Net Working Capital Per Share (Q: Mar. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(209.188+0.75 * 46.665+0.5 * 18.328-81.424
-0-0)/76.4253
=2.25

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Veracyte's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=17.228/31.461*365 / 4
=49.97

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Veracyte's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=31.461 / 17.228
=1.83

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Veracyte's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=17.228 / 96.844
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Veracyte Total Inventories Related Terms

Thank you for viewing the detailed overview of Veracyte's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Veracyte (Veracyte) Business Description

Traded in Other Exchanges
Address
6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis products.
Executives
Phillip G. Febbo officer: Chief Scientific & Med Officer C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
John Leite officer: Chief Commercial Officer-CLIA 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Evan/ Fa Jones director C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
John L Bishop director
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Bonnie H Anderson director, officer: President & CEO 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Karin Eastham director C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Giulia C Kennedy officer: Chief Scientific & Med Officer 338 MAIN STREET #26E, SAN FRANCISCO CA 94105
Eliav Barr director C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Jens Holstein director C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Marc Stapley officer: Chief Executive Officer 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Kevin K Gordon director 155 S LIMERICK RD, LIMERICK PA 19468
Jonathan Wygant officer: VP, Chief Accounting Officer 3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Annie Mcguire officer: SVP, General Counsel C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Rebecca Chambers officer: Chief Financial Officer 3052 ORCHARD DR., SAN JOSE CA 95134

Veracyte (Veracyte) Headlines

From GuruFocus

Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023

By Business Wire Business Wire 06-12-2023